Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 2:43 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 150 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Intermediate Risk Prostate Cancer Clear all
Terminated Not applicable Interventional

Investigator Initiated Trial to Further Evaluate the Safety and Efficacy of Trans-perineal Focal Laser Ablation of Localized Prostate Cancer Using High Frequency Micro-ultrasound Imaging

NCT05826470
View directory record Official record
Conditions
Prostate Cancer, Low-risk or Favorable Intermediate Risk Prostate Cancer Who Are on an Active Surveillance Regimen
Interventions
TRANBERG®|Thermal Therapy System
Device
Lead sponsor
Genesis Research LLC
Network
Eligibility
40 Years to 85 Years · Male only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Dec 10, 2024 · Synced Oct 23, 2026, 2:43 AM EDT
Completed Phase 2Phase 3 Interventional Results available

68Ga-PSMA-11 PET/MRI in Finding Tumors in Patients With Intermediate or High-Risk Prostate Cancer Undergoing Surgery

NCT02678351
View directory record Official record
Conditions
Stage II Prostate Adenocarcinoma, Stage III Prostate Adenocarcinoma
Interventions
68Ga-PSMA-11, Magnetic resonance imaging (MRI), Positron Emission Tomography (PET)
Drug · Procedure
Lead sponsor
Andrei Iagaru
Other
Eligibility
18 Years and older · Male only
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Mar 4, 2022 · Synced Oct 23, 2026, 2:43 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Radiation and Androgen Ablation for Prostate Cancer

NCT01517451
View directory record Official record
Conditions
Adenocarcinoma of the Prostate
Interventions
Radiation Therapy, Androgen Deprivation Therapy (ADT)
Radiation · Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 100 Years · Male only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2025
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Oct 23, 2026, 2:43 AM EDT
Completed No phase listed Observational

Changes in DNA After Radiation Therapy in Patients With Prostate Cancer

NCT00899912
View directory record Official record
Conditions
Prostate Cancer
Interventions
microarray analysis, diagnostic laboratory biomarker analysis
Genetic · Other
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older · Male only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
10
States / cities
Atlanta, Georgia • Springfield, Illinois • City of Saint Peters, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2015 · Synced Oct 23, 2026, 2:43 AM EDT
Recruiting Phase 2 Interventional

Androgen-responsive POSLUMA-guided Intra-prostatic Boost

NCT07393867
View directory record Official record
Conditions
Intermediate Risk Prostate Cancer, High Risk Prostate Cancer, Prostate Cancer
Interventions
PSMA PET/CT, Androgen Deprivation Therapy (ADT) +/- bicalutamide, Stereotactic Body Radiation Therapy (SBRT) +/- focal microboost
Diagnostic Test · Drug · Radiation
Lead sponsor
Martin T. King, MD, PhD
Other
Eligibility
18 Years and older · Male only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
4
States / cities
Boston, Massachusetts • Milford, Massachusetts • Weymouth, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 23, 2026, 2:43 AM EDT
Approved For Marketing No phase listed Expanded access

18F-DCFPyL PET/MRI in Regional Nodal&Distant Metastases Detection in Intermediate &HR Prostate Cancer

NCT04809584
View directory record Official record
Conditions
Prostate Cancer
Interventions
F18-DCFPyL, Gadolinium, Positron emission tomography (PET)/Magnetic Resonance Imaging (MRI) Scan
Drug · Procedure
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older · Male only
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Dec 19, 2024 · Synced Oct 23, 2026, 2:43 AM EDT
Completed Not applicable Interventional

Ablation of Prostate Tissue Utilizing Sterile Water Vapor in Patients With Intermediate Risk Localized Prostate Cancer

NCT04087980
View directory record Official record
Conditions
Prostate Cancer
Interventions
Poseidon System
Device
Lead sponsor
Francis Medical Inc.
Industry
Eligibility
45 Years to 80 Years · Male only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
5
States / cities
Baltimore, Maryland • Minneapolis, Minnesota • Woodbury, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2022 · Synced Oct 23, 2026, 2:43 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Gallium-68 PSMA-11 PET in Intermediate to High-risk Preprostatectomy Patients

NCT02919111
View directory record Official record
Conditions
Prostate Cancer
Interventions
Ga-68 labeled PSMA-11 PET
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older · Male only
Enrollment
299 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Dec 10, 2020 · Synced Oct 23, 2026, 2:43 AM EDT
Recruiting Phase 2 Interventional

A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec

NCT07332000
View directory record Official record
Conditions
Prostate Cancer Patients Treated by Radiotherapy, Prostate Cancer (Adenocarcinoma)
Interventions
aglatimagene besadenovec + valacyclovir, External Beam Radiation Therapy (EBRT)
Biological · Radiation
Lead sponsor
Candel Therapeutics, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
7
States / cities
Peoria, Arizona • Lakewood, Colorado • Littleton, Colorado + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 23, 2026, 2:43 AM EDT
Recruiting Phase 3 Interventional

Comparing Two Different Boost Approaches in Radiation Therapy for People With Prostate Cancer

NCT07548164
View directory record Official record
Conditions
Prostate Cancer
Interventions
NanoKnife System, Stereotactic Body Radiation Therapy
Device · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Male only
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
8
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 23, 2026, 2:43 AM EDT
Active, not recruiting Phase 2 Interventional

EBRT and HDR Brachytherapy for Unfavorable-intermediate, High, and Very High-risk Prostate Cancer

NCT04465500
View directory record Official record
Conditions
Prostate Cancer, Prostate Adenocarcinoma
Interventions
External Beam Radiation, HDR Brachytherapy, Androgen Deprivation Therapy
Radiation · Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Oct 23, 2026, 2:43 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Stereotactic Body Radiation Therapy in Treating Patients With Prostate Cancer

NCT00547339
View directory record Official record
Conditions
Prostate Cancer
Interventions
stereotactic body radiation therapy (SBRT)- 45 Gy, stereotactic body radiation therapy (SBRT) - 47.5 Gy, stereotactic body radiation therapy (SBRT) - 50 Gy (Phase 1), stereotactic body radiation therapy (SBRT) - 50 Gy (Phase 2)
Radiation
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 120 Years · Male only
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2022
U.S. locations
5
States / cities
Aurora, Colorado • Orlando, Florida • Minneapolis, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2022 · Synced Oct 23, 2026, 2:43 AM EDT
Recruiting Phase 1 Interventional

Evaluation of Neoadjuvant Xaluritamig in Localized Prostate Cancer

NCT06613100
View directory record Official record
Conditions
Prostate Cancer
Interventions
Xaluritamig, GnRH Antagonist
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older · Male only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
7
States / cities
San Francisco, California • St Louis, Missouri • Columbus, Ohio + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 23, 2026, 2:43 AM EDT
Active, not recruiting Not applicable Interventional

Water Vapor Ablation for Localized Intermediate Risk Prostate Cancer

NCT05683691
View directory record Official record
Conditions
Prostate Cancer
Interventions
Vanquish System
Device
Lead sponsor
Francis Medical Inc.
Industry
Eligibility
50 Years and older · Male only
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
25
States / cities
Phoenix, Arizona • Laguna Hills, California • Los Angeles, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Oct 23, 2026, 2:43 AM EDT
Active, not recruiting Phase 3 Interventional

Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer

NCT06235151
View directory record Official record
Conditions
Prostate Cancer, Prostate Adenocarcinoma
Interventions
Copper Cu 64 PSMA I&T
Drug
Lead sponsor
Curium US LLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
439 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
43
States / cities
Homewood, Alabama • Little Rock, Arkansas • Fullerton, California + 35 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 23, 2026, 2:43 AM EDT
Terminated Phase 3 Interventional

Randomized Trial of PSMA PET Scan Before Definitive Radiation Therapy for Prostate Cancer

NCT04457245
View directory record Official record
Conditions
Stage I Prostate Cancer American Joint Committee on Cancer (AJCC) v8, Stage II Prostate Cancer AJCC v8, Stage IIA Prostate Cancer AJCC v8, Stage IIB Prostate Cancer AJCC v8, Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8, Stage IIIB Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8
Interventions
Computed Tomography, Fluorine F 18 DCFPyL, Positron Emission Tomography, Radiation Therapy
Procedure · Other · Radiation
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 17, 2023 · Synced Oct 23, 2026, 2:43 AM EDT
Active, not recruiting Phase 1 Interventional

A Pilot Study of Ultra-High-Dose Hypofractionated or Single-Dose Radiotherapy for Intermediate Risk Prostate Cancer

NCT04147806
View directory record Official record
Conditions
Prostate Cancer
Interventions
IGRT 45 Gy in 5 fractions of 9 Gy, IGRT 24 Gy single dose, Dexamethasone, Tamsulosin
Radiation · Drug
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
50 Years and older · Male only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Apr 3, 2026 · Synced Oct 23, 2026, 2:43 AM EDT
Not listed No phase listed Observational

Multi-Institutional Registry for Prostate Cancer Radiosurgery

NCT01226004
View directory record Official record
Conditions
Prostate Cancer Early Risk Treated by Radiosurgery, Prostate Cancer Intermediate Risk Treated by Radiosurgery
Interventions
Not listed
Lead sponsor
RPCR, Inc.
Other
Eligibility
18 Years to 90 Years · Male only
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2020
U.S. locations
44
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 39 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2019 · Synced Oct 23, 2026, 2:43 AM EDT
Recruiting Not applicable Interventional

Adaptive Radiation Therapy for Men With Intermediate- or High-Risk Prostate Cancer

NCT07219303
View directory record Official record
Conditions
Prostate Cancer (Adenocarcinoma)
Interventions
adaptive stereotactic body radiation therapy (SBRT) with a SIB
Radiation
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2033
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced Oct 23, 2026, 2:43 AM EDT
Completed Phase 3 Interventional

Radiation Therapy With or Without Bicalutamide and Goserelin in Treating Patients With Prostate Cancer

NCT00067015
View directory record Official record
Conditions
Prostate Cancer
Interventions
bicalutamide, goserelin acetate, assessment of therapy complications, quality-of-life assessment, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 120 Years · Male only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 22, 2015 · Synced Oct 23, 2026, 2:43 AM EDT
Completed Phase 3 Interventional Results available

Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer

NCT00005044
View directory record Official record
Conditions
Prostate Cancer
Interventions
Casodex, Eulexin, LHRH agonist, radiation therapy
Drug · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years to 120 Years · Male only
Enrollment
1,579 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2022
U.S. locations
241
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 181 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2022 · Synced Oct 23, 2026, 2:43 AM EDT
Completed Phase 2 Interventional Results available

Study of the Efficacy, Safety and Quality of Life After TOOKAD® Soluble (VTP) for Intermediate Risk Prostate Cancer.

NCT03315754
View directory record Official record
Conditions
Localized Prostate Cancer
Interventions
TOOKAD Soluble 4 mg/kg
Drug
Lead sponsor
Steba Biotech S.A.
Other
Eligibility
18 Years and older · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 23, 2026, 2:43 AM EDT
Completed Phase 1 Interventional

Neoadjuvant J591 Treatment for Prostate Cancer

NCT02693860
View directory record Official record
Conditions
Prostate Cancer
Interventions
huJ591, 89Zr-J591
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older · Male only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 5, 2020 · Synced Oct 23, 2026, 2:43 AM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Observation of Outcomes and Side Effects of Cesium-131 in Combination With External Beam Radiation for the Treatment of Intermediate to High Risk Prostate Cancer

NCT00621413
View directory record Official record
Conditions
Prostate Cancer
Interventions
Not listed
Lead sponsor
IsoRay Medical, Inc.
Industry
Eligibility
18 Years and older · Male only
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
9
States / cities
Phoenix, Arizona • Rancho Mirage, California • San Mateo, California + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2021 · Synced Oct 23, 2026, 2:43 AM EDT